Amna Sheri

450 total citations
20 papers, 306 citations indexed

About

Amna Sheri is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amna Sheri has authored 20 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amna Sheri's work include Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Amna Sheri is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Amna Sheri collaborates with scholars based in United Kingdom, United States and Belgium. Amna Sheri's co-authors include Mitch Dowsett, Stephen Johnston, Ian E. Smith, Robin L. Jones, Margaret Hills, Justin D. Salciccioli, Joseph Shalhoub, Dominic C. Marshall, Maggie C.U. Cheang and W. Fraser Symmans and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Amna Sheri

16 papers receiving 300 citations

Peers

Amna Sheri
Tomoyuki Aruga Japan
Benlong Yang China
Valentina Magri Italy
Liisa Sailas Finland
Shaheenah Dawood United Arab Emirates
Rodrigo Gonçalves Brazil
Lauren Nye United States
Antonia Márquez Spain
Wenjing Zhou Sweden
Thomas P. Potjer Netherlands
Tomoyuki Aruga Japan
Amna Sheri
Citations per year, relative to Amna Sheri Amna Sheri (= 1×) peers Tomoyuki Aruga

Countries citing papers authored by Amna Sheri

Since Specialization
Citations

This map shows the geographic impact of Amna Sheri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amna Sheri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amna Sheri more than expected).

Fields of papers citing papers by Amna Sheri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amna Sheri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amna Sheri. The network helps show where Amna Sheri may publish in the future.

Co-authorship network of co-authors of Amna Sheri

This figure shows the co-authorship network connecting the top 25 collaborators of Amna Sheri. A scholar is included among the top collaborators of Amna Sheri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amna Sheri. Amna Sheri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sennfält, Stefan, Amna Sheri, Emine Hatipoglu, et al.. (2025). Gastrointestinal Dysautonomia After Immune Checkpoint Inhibitor Therapy: A Case Series and Systematic Review. Neurogastroenterology & Motility. 38(1). e70212–e70212.
2.
3.
Lorigan, Paul, Theresa Medina, Marta Nyakas, et al.. (2024). Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.. Journal of Clinical Oncology. 42(17_suppl). LBA9519–LBA9519. 3 indexed citations
4.
Edner, Natalie M., Elisavet Ntavli, Lina Petersone, et al.. (2023). Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. PubMed. 3(1). ltad001–ltad001. 4 indexed citations
5.
Okines, Alicia, Jeremy Braybrooke, Iain R. Macpherson, et al.. (2023). Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).. Journal of Clinical Oncology. 41(16_suppl). TPS1111–TPS1111. 2 indexed citations
6.
7.
Salciccioli, Justin D., et al.. (2020). Trends in malignant melanoma mortality in 31 countries from 1985 to 2015*. British Journal of Dermatology. 183(6). 1056–1064. 41 indexed citations
8.
Law, Steven, et al.. (2019). The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma. Melanoma Research. 30(3). 321–324. 5 indexed citations
9.
Sheri, Amna, Ian E. Smith, Margaret Hills, et al.. (2017). Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 164(2). 395–400. 10 indexed citations
10.
Dodson, Andrew, L. Assersohn, Anne Rigg, et al.. (2017). Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. Breast Cancer Research and Treatment. 168(1). 249–258. 6 indexed citations
11.
Klintman, Marie, Richard Buus, Maggie C.U. Cheang, et al.. (2016). Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. Clinical Cancer Research. 22(10). 2405–2416. 38 indexed citations
12.
Buus, Richard, Marie Klintman, Amna Sheri, Maggie C.U. Cheang, & Mitch Dowsett. (2015). Abstract 5294: Biomarkers in residual disease after neoadjuvant chemotherapy of breast cancer predict long-term outcome. Cancer Research. 75(15_Supplement). 5294–5294. 1 indexed citations
13.
Noujaim, Jonathan, Khin Thway, Amna Sheri, Charles Keller, & Robin L. Jones. (2015). Histology-Driven Therapy. International Journal of Surgical Pathology. 24(1). 5–15. 30 indexed citations
14.
Sheri, Amna, Ian E. Smith, Stephen Johnston, et al.. (2014). Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Annals of Oncology. 26(1). 75–80. 78 indexed citations
15.
Sheri, Amna & Mitch Dowsett. (2012). Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Annals of Oncology. 23. x219–x227. 46 indexed citations
16.
Sheri, Amna & Stephen Johnston. (2012). New Developments and Future Directions in Systemic Therapy. Clinical Oncology. 25(2). 117–126. 9 indexed citations
17.
Sheri, Amna & Mitch Dowsett. (2011). Predicting response to cytotoxic drugs – the endocrine part of the story. The Breast. 20. S28–S30.
18.
Sheri, Amna, Lesley‐Ann Martin, & Stephen Johnston. (2010). Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?. Clinical Breast Cancer. 10. S79–S85. 20 indexed citations
19.
Dolly, Saoirse, Amna Sheri, Marina Parton, et al.. (2010). Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?. Oncology. 79(5-6). 331–336. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoyuki Aruga Breakdown of academic impact, for papers by Benlong Yang Breakdown of academic impact, for papers by Valentina Magri Breakdown of academic impact, for papers by Liisa Sailas Breakdown of academic impact, for papers by Shaheenah Dawood Breakdown of academic impact, for papers by Rodrigo Gonçalves Breakdown of academic impact, for papers by Lauren Nye Breakdown of academic impact, for papers by Antonia Márquez Breakdown of academic impact, for papers by Wenjing Zhou Breakdown of academic impact, for papers by Thomas P. Potjer
Rankless by CCL
2026